COMMUNIQUÉS West-GlobeNewswire

CapsoVision annonce l'obtention du marquage CE pour l'utilisation de sa vidéo-capsule CapsoCam Plus chez les patients âgés de 2 ans et plus
30/10/2017
La technologie disruptive de CapsoCam Plus offre des images latérales panoramiques de 360º et leur enregistrement dans la capsule, éliminant ainsi le recours à des équipements externes. SARATOGA, Californie, le 25 [...]
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
30/10/2017
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera ® , a first-in-class RadioLigand Therapy (RLT) approved in Europe and [...]
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
28/10/2017
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease modifying therapies for children and [...]
ABLYNX CLOSES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES
27/10/2017
REGULATED INFORMATION GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments [...]
uniQure Announces Closing of its Public Offering
27/10/2017
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 27, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical [...]
UPDATE -- CapsoVision, Inc. Announces CE Mark for the Use of CapsoCam Plus Capsule Endoscopy System in Patients Ages 2 and Above*
27/10/2017
Award-winning technology provides 360º imaging, eliminates need for receiver equipment during examination SARATOGA, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Today Silicon Valley-based CapsoVision, Inc. announced CE [...]
NEOVACS : RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES
27/10/2017
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES FIN DU RECRUTEMENT DES PATIENTS DANS L'ÉTUDE CLINIQUE DE PHASE IIb AVEC l'IFNalpha [...]
NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS
27/10/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS COMPLETED PATIENT ENROLLMENT IN PHASE IIb CLINICAL STUDY OF IFNalpha KINOID FOR TREATMENT OF [...]
Shire plc : 3rd Quarter Results
27/10/2017
Shire reports strong earnings growth in Q3 2017; reiterates full year guidance Product sales increased 7%, mainly driven by rapid growth in Immunology franchise Generated $1.1 billion operating cash flow; remain on- [...]
Preferred Dental Technologies Inc. ("Company") (CSE: PDT): Addresses the growing digital dentistry market
27/10/2017
Prototypes for EAS have been successfully created in multiple materials WINNIPEG, Manitoba, Oct. 27, 2017 (GLOBE NEWSWIRE) -- PDT's Evolutionary Accessory Series (EAS) is used to create custom dental abutments for the [...]
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
27/10/2017
Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of oncology medicine filgrastim [...]
Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
27/10/2017
The board of directors of Targovax ASA (the "Company") has on 27 October 2017, in accordance with the authorisations granted by the general meeting on 5 April 2017, resolved: - to increase the share capital of up to NOK [...]
Vistin Pharma ASA : Third quarter 2017 results - strong growth, capacity expansion on track
27/10/2017
Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) experienced strong growth in the third quarter of 2017, with a 20 per cent increase in revenue from its metformin business. With a strong financial [...]
ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD
27/10/2017
REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform [...]
Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline
26/10/2017
Galapagos Q3 Results This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Composition of the Nomination Committee of Orion Corporation
26/10/2017
ORION CORPORATION STOCK EXCHANGE RELEASE 26 OCTOBER 2017 at 18.45 P.M. EEST Composition of the Nomination Committee of Orion Corporation The Board of Directors of Orion Corporation has elected the following persons to [...]
Origin(TM) Announces Positive Interim Results from Phase IIb Dose-Ranging Study for Diabetic Foot Ulcers
26/10/2017
Interim results demonstrate strong evidence of healing and favorable safety profile Highest-performing arm (4X per week, 12 minutes): · 95% mean wound-size reduction in 12 weeks · 71% of wounds achieved complete healing [...]
Inivata Announces World-Leading Scientific Advisory Board
26/10/2017
Inivata Announces World-Leading Scientific Advisory Board Research Triangle Park, NC and Cambridge, UK, 26 October2017 -- Inivata , a global clinical cancer genomics company utilizing an industry-leading liquid biopsy [...]
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
26/10/2017
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' third quarter [...]

Pages